Kimberly-Clark to buy maker of Tylenol
Digest more
Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings ...
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its ...
Kimberly-Clark N/A said on Monday it will acquire Tylenol maker Kenvue KVUE-N +0.91% in a deal valued at about ...
Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when ...
1don MSN
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.
The major stock indexes were mixed on Monday, at the outset of another busy week of quarterly earnings reports and the release of key private sector employment data.
Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.
Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback